Somatostatin analogue treatment

Somatostatin analogues are particularly useful for ameliorating clinical symptoms such as diarrhoea and flushing related to carcinoid tumours. They also demonstrate some anti-tumour effects with about 10% of patients showing significant tumour reduction and 30-40%, stabilization of the disease. High-dose therapy (>3 mg/day) has been shown to induce apoptosis in carcinoid tumours.

Their parenteral administration is simplified with the recently marketed long-acting formulations (10-30 mg intramuscular injection monthly).

0 0

Post a comment